Видео ютуба по тегу Trial: Keynote-585

Final analysis of KEYNOTE-585: pembrolizumab and chemotherapy in G/GEJ cancer
Final analysis of KEYNOTE-585: pembrolizumab and chemotherapy in G/GEJ cancer
KEYNOTE-585: perioperative pembrolizumab in stomach cancers
KEYNOTE-585: perioperative pembrolizumab in stomach cancers
KEYNOTE-585: mPR and tumor downstaging as surrogate endpoints in G/GEJ
KEYNOTE-585: mPR and tumor downstaging as surrogate endpoints in G/GEJ
Developments in gastric and gastroesophageal cancer management
Developments in gastric and gastroesophageal cancer management
Perioperative pembrolizumab for stomach cancer treatment
Perioperative pembrolizumab for stomach cancer treatment
FDA Approves Keytruda / Pembrolizumab for HER2+ Gastric/GEJ Cancer with PD-L1
FDA Approves Keytruda / Pembrolizumab for HER2+ Gastric/GEJ Cancer with PD-L1
Периоперационная иммунотерапия при раке желудка и ГЭП
Периоперационная иммунотерапия при раке желудка и ГЭП
KEYNOTE-775: Ленватиниб + Пембролизумаб в лечении распространённого эндометриального рака
KEYNOTE-775: Ленватиниб + Пембролизумаб в лечении распространённого эндометриального рака
Keynote Presentation: The Grand Challenge of Cancer Disparities
Keynote Presentation: The Grand Challenge of Cancer Disparities
Общая выживаемость при применении пембролизумаба при раке молочной железы | NEJM
Общая выживаемость при применении пембролизумаба при раке молочной железы | NEJM
Keynote: Deciphering oncohistone pathogenesis in Cancer
Keynote: Deciphering oncohistone pathogenesis in Cancer
Final overall survival results from KEYNOTE-811 in HER2+ metastatic gastric cancer
Final overall survival results from KEYNOTE-811 in HER2+ metastatic gastric cancer
Long term survival data from the Phase III Keynote-054 trial
Long term survival data from the Phase III Keynote-054 trial
Modernizing Oncology Endpoints: Pathways for Evidence and Policy
Modernizing Oncology Endpoints: Pathways for Evidence and Policy
Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free ...
Adjuvant pembrolizumab in resected merkel cell carcinoma shows improved distant metastasis-free ...
Immunotherapy + Chemotherapy: The MATTERHORN Breakthrough in Gastric Cancer
Immunotherapy + Chemotherapy: The MATTERHORN Breakthrough in Gastric Cancer
The KEYNOTE-001 trial: A breakthrough for pembrolizumab
The KEYNOTE-001 trial: A breakthrough for pembrolizumab
Hepatitis B outcomes in KEYNOTE-966: HBV+ pts on pembrolizumab + gem/cis for advanced BTC
Hepatitis B outcomes in KEYNOTE-966: HBV+ pts on pembrolizumab + gem/cis for advanced BTC
KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC
KEYNOTE-522: final OS findings of pembrolizumab and chemotherapy in TNBC
Основной доклад: Сопутствующая диагностика: технические, клинические и коммерческие проблемы...
Основной доклад: Сопутствующая диагностика: технические, клинические и коммерческие проблемы...
Updates in EV-pembrolizumab MIBC from the KEYNOTE-905/EV-303 trial
Updates in EV-pembrolizumab MIBC from the KEYNOTE-905/EV-303 trial